Technology Listings

Broad Spectrum Vaccine to Human Rhinovirus Serotypes


A vaccine that provides protection from a broad spectrum of human rhinovirus serotypes.

Key Benefits
  • Targets numerous, specific human rhinovirus (HRV) serotypes and provides broad neutralizing antibodies.
  • Engineered bacterial artificial chromosome (BAC) expression of HRV to reproducibly express specific serotypes.
  • BAC system allows for genetic manipulation of HRV to produce recombinant strains of virus potentially improving vaccine effectiveness.
Market Summary

Human rhinovirus (HRV) is the most common virus infecting humans, primarily impacting the nose, throat (pharynx) and sinuses and is typically attributed as the virus causing a “common cold.” HRV infections can lead to serious complications in immunocompromised, aged and young patients. HRV possesses a serious risk in asthmatics as 50% of acute asthma attacks in children are due to complications from a “cold.” A major hurdle in vaccine development for HRV is the existence of more than 100 serotypes of the virus. Specific documentation is required for each serotype regarding its clinical isolation during the production of a vaccine composed of multiple inactivated HRV serotypes. The identification of HRV serotypes that provide the most cross protection and a system to rapidly produce them could lead to an effective vaccine against HRV.

Technology Summary

Dr. Marty Moore’s lab has developed a vaccine against a broad spectrum of human rhinovirus (HRV) serotypes. A BAC system was generated to produce HRV serotypes from a man-made plasmid rather than a clinical sample. This system allows for the genetic manipulation of the encoded HRV for the production of alternative serotypes or chimeric viruses composed of capsid proteins from various serotypes. These advances allow the production of a vaccine generated from pooled serotypes of inactivated HRV to provide a broad spectrum of protection from HRV.

Developmental Stage
  • Serotypes of human rhinovirus that provide broad immunogenicity against HRV Species A have been identified.
  • HRV variants generated utilizing the BAC system are being tested in animals.
Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Nationalized PCT - Foreign Canada 2,989,332   12/12/2017    
Nationalized PCT - Foreign Japan 2017-564597   12/12/2017    
Nationalized PCT - Foreign China 201680034539.6   12/13/2017    
Nationalized PCT - Foreign EP 16812353.7   12/14/2017    
Nationalized PCT - Foreign United States 15/737,239 12/15/2017    
Nationalized PCT - Foreign Korea, Republic of 10-2018-7001071   1/12/2018    
Tech ID: 14212
Published: 3/16/2016
Drug Discovery

Cliff Michaels
Assistant Director
Emory University

Martin Moore
Minh Nguyen
Sujin Lee

Microbiology/Infectious Diseases